Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Actuarialon Aug 13, 2018 12:45pm

87 Views

Post# 28450491

RE:S&M...Ed

My bad, it is not 14 but 12. It is quite normal such a small size for Ph 2A. As I explained in another post, if you observed a p-value in a small size trial, you would normally expect a even improved p-value (i.e., smaller) in a large trial.

"Twelve patients with OA of the knee were treated once daily for 10 days with ATB-346 at a dose of 250 mg.

I didn't see where it says there were more at the beginning unless your talking about Ph 1, when a few patient with pre-existing conditions with liver problem lies before entering the trial.

https://www.antibethera.com/2016/08/08/antibe-therapeutics-announces-successful-phase-2-trial-of-atb-346-in-osteoarthritis/

Bullboard Posts

Changing Europe’s dependency on HREE from China